News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Staff Note Financial Ties in Zimmer Holdings Inc. Spine Study
November 3, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. reviewers have raised the possibility of bias in the evaluation of a spine device made by Zimmer Holdings Inc (ZMH.N), saying a majority of patients in a study were treated by researchers with a financial interest in the company.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Regulatory
It’s Official: FDA Will Now Default to One Clinical Trial for Drug Applications
February 19, 2026
·
3 min read
·
Tristan Manalac
CDC
NIH’s Jay Bhattacharya Steps In as Acting CDC Chief
February 18, 2026
·
1 min read
·
Annalee Armstrong
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
·
3 min read
·
Heather McKenzie
Legal
Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus
February 18, 2026
·
2 min read
·
Tristan Manalac